BriaCell Therapeutics Corp.
BCTX
$3.62
-$0.0292-0.80%
| 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | 10/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -19.09% | -21.92% | 3.07% | 5.12% | -3.37% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.68% | 43.22% | 69.55% | 64.78% | 43.27% |
| Operating Income | -13.68% | -43.22% | -69.55% | -64.78% | -43.27% |
| Income Before Tax | -26.31% | 75.71% | 66.72% | 45.90% | -3,112.86% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -26.31% | 75.71% | 66.72% | 45.90% | -3,112.86% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 191.57% | -- | -- | -- | -- |
| Net Income | -25.77% | 76.40% | 67.30% | 46.25% | -3,102.52% |
| EBIT | -13.68% | -43.22% | -69.55% | -64.78% | -43.27% |
| EBITDA | -13.34% | -42.95% | -69.60% | -64.83% | -43.31% |
| EPS Basic | -3.19% | 77.64% | 68.20% | 47.39% | -1,781.84% |
| Normalized Basic EPS | -2.92% | 78.03% | 68.54% | 47.60% | -1,778.28% |
| EPS Diluted | 48.65% | 11.02% | -4.96% | -10.12% | -142.40% |
| Normalized Diluted EPS | -1.06% | 76.83% | 67.21% | 46.56% | -496.73% |
| Average Basic Shares Outstanding | 21.51% | 5.35% | 2.90% | 2.41% | 1.22% |
| Average Diluted Shares Outstanding | 20.18% | 6.46% | 4.01% | 3.53% | -1.80% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
